The International Workshop on HIV Persistence during Therapy is, historically, the first meeting centered on HIV reservoirs. In 2003, a group of researchers understood the need for a regular meeting focused on new findings from basic to clinical science on the persistence of HIV.
HIV reservoirs were only described at the end of 1997 and it was clear that they were the main obstacles toward HIV eradication. At that time it was not a research priority and most groups were rather interested by the management of cART side effects.
However, in 2005, during the second edition of the workshop, the first results of a clinical trial using HDAC inhibitors to reverse latency within the HIV reservoir were presented.
In 2009, during the fourth edition, attendees were presented with a case of
a Berlin patient who fuelled hope in the field of an HIV cure.
Mechanisms of HIV persistence and new strategies toward HIV eradication became the high priority for research agencies and governments. Since its start, the HIV Persistence during Therapy Workshop has welcomed the main leaders in this challenging field who have shared their cutting edge work in oral or poster presentation form with the support of NIH, ANRS, and other organizations.
Growing from 90 participants in 2003 to over 400 participants in 2022, it is recognized as the reference workshop on HIV reservoirs and cure by the scientific community.
The members of the Steering and Scientific Committees are well renowned scientists publishing regularly in high impact journals.
Over four days, the workshop covers basic to clinical science, virologic, immunologic and pharmacologic aspects of HIV persistence, and is attended by basic science researchers, virologists, immunologists and clinicians. Broad participation enables important exchanges between diverse workers in the field. The workshop seeks to involve others outside HIV research that contribute to future advances.
The HIV Persistence during Therapy Workshop is dedicated to progress towards the end of the HIV pandemic.